These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

867 related articles for article (PubMed ID: 16968945)

  • 1. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.
    Kontush A; Chapman MJ
    Pharmacol Rev; 2006 Sep; 58(3):342-74. PubMed ID: 16968945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiatherogenic small, dense HDL--guardian angel of the arterial wall?
    Kontush A; Chapman MJ
    Nat Clin Pract Cardiovasc Med; 2006 Mar; 3(3):144-53. PubMed ID: 16505860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
    Chapman MJ
    Pharmacol Ther; 2006 Sep; 111(3):893-908. PubMed ID: 16574234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.
    Chapman MJ; Guérin M; Bruckert E
    Eur Heart J; 1998 Feb; 19 Suppl A():A24-30. PubMed ID: 9519339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities.
    Kontush A; Chapman MJ
    Curr Opin Lipidol; 2010 Aug; 21(4):312-8. PubMed ID: 20581677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-density lipoprotein function recent advances.
    Ansell BJ; Watson KE; Fogelman AM; Navab M; Fonarow GC
    J Am Coll Cardiol; 2005 Nov; 46(10):1792-8. PubMed ID: 16286161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis.
    Sherman CB; Peterson SJ; Frishman WH
    Cardiol Rev; 2010; 18(3):141-7. PubMed ID: 20395699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-density lipoprotein as a key component in the prevention of premature atherosclerotic disease in the insulin resistance syndrome.
    Hansel B; Kontush A; Twickler MT
    Semin Vasc Med; 2004 May; 4(2):215-23. PubMed ID: 15478044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.
    Vaziri ND
    J Ren Nutr; 2010 Sep; 20(5 Suppl):S35-43. PubMed ID: 20797569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
    Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
    Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence.
    Nofer JR; Walter M; Assmann G
    Expert Rev Cardiovasc Ther; 2005 Nov; 3(6):1071-86. PubMed ID: 16292998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDL function as a target of lipid-modifying therapy.
    Watson KE; Ansell BJ; Watson AD; Fonarow GC
    Rev Cardiovasc Med; 2007; 8(1):1-8. PubMed ID: 17401296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiinflammatory properties of HDL.
    Barter PJ; Nicholls S; Rye KA; Anantharamaiah GM; Navab M; Fogelman AM
    Circ Res; 2004 Oct; 95(8):764-72. PubMed ID: 15486323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small, dense high-density lipoprotein 3 particles exhibit defective antioxidative and anti-inflammatory function in familial hypercholesterolemia: Partial correction by low-density lipoprotein apheresis.
    Hussein H; Saheb S; Couturier M; Atassi M; Orsoni A; Carrié A; Therond P; Chantepie S; Robillard P; Bruckert E; Chapman MJ; Kontush A
    J Clin Lipidol; 2016; 10(1):124-33. PubMed ID: 26892129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity.
    de Souza JA; Vindis C; Hansel B; Nègre-Salvayre A; Therond P; Serrano CV; Chantepie S; Salvayre R; Bruckert E; Chapman MJ; Kontush A
    Atherosclerosis; 2008 Mar; 197(1):84-94. PubMed ID: 17868679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological activities of HDL subpopulations and their relevance to cardiovascular disease.
    Camont L; Chapman MJ; Kontush A
    Trends Mol Med; 2011 Oct; 17(10):594-603. PubMed ID: 21839683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-density lipoproteins: multifunctional vanguards of the cardiovascular system.
    Marcil M; O'Connell B; Krimbou L; Genest J
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):417-30. PubMed ID: 15151487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease.
    Miller M; Ginsberg HN; Schaefer EJ
    Am J Cardiol; 2008 Apr; 101(7):1003-8. PubMed ID: 18359322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.